{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:40:31Z","timestamp":1787586031893,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"am","delay-in-days":212,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005965","name":"Kanazawa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["GHIT T2019-252"],"award-info":[{"award-number":["GHIT T2019-252"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nk0101539"],"award-info":[{"award-number":["JP21nk0101539"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["193298"],"award-info":[{"award-number":["193298"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H03458"],"award-info":[{"award-number":["19H03458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06559"],"award-info":[{"award-number":["21K06559"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.parint.2022.102652","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T23:01:31Z","timestamp":1661209291000},"page":"102652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adeno-associated virus-based malaria booster vaccine following attenuated replication-competent vaccinia virus LC16m8\u0394 priming"],"prefix":"10.1016","volume":"92","author":[{"given":"Ammar A.","family":"Hasyim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Iyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iroha","family":"Yamagoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenni","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intan","family":"Syafira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahnaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7715","key":"10.1016\/j.parint.2022.102652_bb0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-018-0318-5","article-title":"Challenges and opportunities in controlling mosquito-borne infections","volume":"559","author":"Ferguson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.parint.2022.102652_bb0010","series-title":"World Malaria Report 2021","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.parint.2022.102652_bb0015","article-title":"Vaccination: the cornerstone of an efficient healthcare system","volume":"3","author":"Remy","year":"2015","journal-title":"J. Mark. Access Health Policy"},{"key":"10.1016\/j.parint.2022.102652_bb0020","series-title":"Department of Immunization, Vaccines and Biologicals (IVB)","article-title":"Full Evidence Report on the RTS,S\/AS01 Malaria Vaccine","author":"World Health Organization","year":"2021"},{"issue":"3","key":"10.1016\/j.parint.2022.102652_bb0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"52","key":"10.1016\/j.parint.2022.102652_bb0030","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1016\/j.vaccine.2015.09.111","article-title":"Building an effective malaria vaccine pipeline to address global needs","volume":"33","author":"Birkett","year":"2015","journal-title":"Vaccine"},{"issue":"9906","key":"10.1016\/j.parint.2022.102652_bb0035","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(13)62238-2","article-title":"Malaria vaccine technology roadmap","volume":"382","author":"Moorthy","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.parint.2022.102652_bb0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral vector malaria vaccines induce high-level T cell and antibody responses in west African children and infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol. Ther."},{"issue":"52","key":"10.1016\/j.parint.2022.102652_bb0045","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2015.09.094","article-title":"Progress with viral vectored malaria vaccines: a multi-stage approach involving \u201cunnatural immunity\u201d","volume":"33","author":"Ewer","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.parint.2022.102652_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/gt.2010.105","article-title":"Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution","volume":"18","author":"Prasad","year":"2011","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.parint.2022.102652_bb0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.parint.2022.102652_bb0060","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.parint.2022.102652_bb0065","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/srep01832","article-title":"Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy","volume":"3","author":"Sen","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parint.2022.102652_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-642-00477-3_5","article-title":"Viral vectors for gene transfer: current status of gene therapeutics","volume":"197","author":"Heilbronn","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.parint.2022.102652_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.parint.2022.102652_bb0080","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.parint.2022.102652_bb0085","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.parint.2022.102652_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.mt.6300377","article-title":"Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles","volume":"16","author":"Lorain","year":"2008","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.parint.2022.102652_bb0095","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.parint.2022.102652_bb0100","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fimmu.2019.00730","article-title":"Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2022.102652_bb0105","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3389\/fimmu.2019.02412","article-title":"A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2022.102652_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612910","article-title":"Liver-directed AAV8 booster vaccine expressing plasmodium falciparum antigen following adenovirus vaccine priming elicits sterile protection in a murine model","volume":"12","author":"Shahnaij","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.parint.2022.102652_bb0115","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J. Med. Virol."},{"issue":"7\u20138","key":"10.1016\/j.parint.2022.102652_bb0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/hum.2021.243","article-title":"Higher Seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States","volume":"33","author":"Khatri","year":"2022","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.parint.2022.102652_bb0125","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.parint.2022.102652_bb0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/rth2.12177","article-title":"Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia a","volume":"3","author":"Stanford","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"21","key":"10.1016\/j.parint.2022.102652_bb0135","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.parint.2022.102652_bb0140","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1128\/JVI.74.8.3852-3858.2000","article-title":"Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer","volume":"74","author":"Zabner","year":"2000","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.parint.2022.102652_bb0145","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1128\/JVI.75.13.6199-6203.2001","article-title":"Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer","volume":"75","author":"Hildinger","year":"2001","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.parint.2022.102652_bb0150","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1089\/hum.2009.031","article-title":"Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders","volume":"20","author":"Paneda","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.parint.2022.102652_bb0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3851\/IMP1469","article-title":"Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors","volume":"14","author":"Nieto","year":"2009","journal-title":"Antivir. Ther."},{"issue":"7","key":"10.1016\/j.parint.2022.102652_bb0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2011.202","article-title":"Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques","volume":"23","author":"Nieto","year":"2012","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.parint.2022.102652_bb0165","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia a","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.parint.2022.102652_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia a","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parint.2022.102652_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"9","key":"10.1016\/j.parint.2022.102652_bb0180","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.parint.2022.102652_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029428","article-title":"A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity","volume":"6","author":"Goodman","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.parint.2022.102652_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12498","article-title":"Protective efficacy of an IL-12-expressing baculoviral malaria vaccine","volume":"39","author":"Iyori","year":"2017","journal-title":"Parasite Immunol."},{"issue":"24","key":"10.1016\/j.parint.2022.102652_bb0195","doi-asserted-by":"crossref","first-page":"11899","DOI":"10.1128\/JVI.00890-06","article-title":"Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells","volume":"80","author":"Xin","year":"2006","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.parint.2022.102652_bb0200","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1038\/s41598-018-21369-y","article-title":"Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model","volume":"8","author":"Yoshida","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.parint.2022.102652_bb0205","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/imb.12055","article-title":"Visualization and live imaging analysis of a mosquito saliva protein in host animal skin using a transgenic mosquito with a secreted luciferase reporter system","volume":"22","author":"Yamamoto","year":"2013","journal-title":"Insect Mol. Biol."},{"issue":"1","key":"10.1016\/j.parint.2022.102652_bb0210","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12936-017-2039-x","article-title":"DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice","volume":"16","author":"Iyori","year":"2017","journal-title":"Malar. J."},{"issue":"12","key":"10.1016\/j.parint.2022.102652_bb0215","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/IAI.01056-13","article-title":"Functional comparison of plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay","volume":"81","author":"Miura","year":"2013","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.parint.2022.102652_bb0220","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.4049\/jimmunol.1800908","article-title":"Baculovirus-induced fast-acting innate immunity kills liver-stage plasmodium","volume":"201","author":"Emran","year":"2018","journal-title":"J. Immunol."},{"issue":"6055","key":"10.1016\/j.parint.2022.102652_bb0225","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity","volume":"334","author":"Epstein","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.parint.2022.102652_bb0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/978-1-62703-026-7_40","article-title":"Assessing transmission blockade in plasmodium spp","volume":"923","author":"Blagborough","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"35","key":"10.1016\/j.parint.2022.102652_bb0235","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.vaccine.2016.06.066","article-title":"Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in plasmodium falciparum standard membrane-feeding assay","volume":"34","author":"Miura","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.parint.2022.102652_bb0240","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jgm.686","article-title":"Gene transfer into skeletal muscle using novel AAV serotypes","volume":"7","author":"Louboutin","year":"2005","journal-title":"J. Gene. Med."},{"issue":"47\u201348","key":"10.1016\/j.parint.2022.102652_bb0245","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: an attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.parint.2022.102652_bb0250","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/vaccines2040755","article-title":"Vaccinia virus LC16m8 as a vaccine vector for clinical applications","volume":"2","author":"Kidokoro","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"6673","key":"10.1016\/j.parint.2022.102652_bb0255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.parint.2022.102652_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694759","article-title":"Safety and immunogenicity of ChAd63\/MVA Pfs25-IMX313 in a phase I first-in-human trial","volume":"12","author":"de Graaf","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2022.102652_bb0265","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1038\/srep18848","article-title":"Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.parint.2022.102652_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and immunogenicity of Pfs25-EPA\/Alhydrogel(R), a transmission blocking vaccine against plasmodium falciparum: an open label study in malaria naive adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2022.102652_bb0275","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1073\/pnas.0609885104","article-title":"Long-lasting and transmission-blocking activity of antibodies to plasmodium falciparum elicited in mice by protein conjugates of Pfs25","volume":"104","author":"Kubler-Kielb","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parint.2022.102652_bb0280","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/ncomms2840","article-title":"Transmission-blocking interventions eliminate malaria from laboratory populations","volume":"4","author":"Blagborough","year":"2013","journal-title":"Nat. Commun."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576922001167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576922001167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:36:30Z","timestamp":1761302190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383576922001167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"alternative-id":["S1383576922001167"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2022.102652","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated virus-based malaria booster vaccine following attenuated replication-competent vaccinia virus LC16m8\u0394 priming","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2022.102652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102652"}}